公开(公告)号：US20230203022A1

公开(公告)日：2023-06-29

申请号：US17922124

申请日：2021-04-29

Applicant: Shanghaitech University

Inventor： Xiaobao YANG ,  Biao JIANG ,  Linyi LIU ,  Chaowei REN ,  Xing QIU ,  Haixia LIU ,  Ning SUN ,  Renhong SUN

IPC: C07D405/14 ,  A61K45/06 ,  C07D417/14 ,  C07D401/14 ,  C07D453/02 ,  C07D409/14

CPC classification number: C07D405/14 ,  A61K45/06 ,  C07D401/14 ,  C07D409/14 ,  C07D417/14 ,  C07D453/02

Abstract: The present disclosure relates to compounds of Formula (I) or salts, enantiomers, stereoisomers, solvates, or polymorphs thereof, and uses thereof. The present disclosure also relates to pharmaceutical compositions comprising, as an active ingredient, the compound of Formula (I) or a salt, enantiomer, stereoisomer, solvate, or polymorph thereof, and use thereof. A series of compounds designed and synthesized by the present disclosure can effectively prevent and/or treat diseases or disorders associated with TNF-a.

公开(公告)号：US20230096517A1

公开(公告)日：2023-03-30

申请号：US17801953

申请日：2021-02-25

Applicant: SHANGHAITECH UNIVERSITY

Inventor： Xiaobao YANG ,  Biao JIANG ,  Xing QIU ,  Ning SUN ,  Renhong SUN ,  Chaowei REN

IPC: C07D401/04 ,  A61P35/00

Abstract: The present disclosure relates to glutarimide skeleton-based compounds of Formula (I) or a salt, an enantiomer, a stereoisomer, a solvate, or a polymorph thereof, and uses thereof. The present disclosure further relates to a pharmaceutical composition comprising, as an active ingredient, the glutarimide skeleton-based compounds of Formula (I), or a salt, an enantiomer, a stereoisomer, a solvate, or a polymorph thereof, and uses thereof. The series of compounds designed and synthesized in the present disclosure can effectively prevent and/or treat a tumor.

公开(公告)号：US20220143002A1

公开(公告)日：2022-05-12

申请号：US17433462

申请日：2020-02-25

Applicant: SHANGHAITECH UNIVERSITY

Inventor： Xiaobao YANG ,  Biao JIANG ,  Xing QIU ,  Ning SUN ,  Renhong SUN ,  Linyi LIU ,  Chaowei REN

IPC: A61K31/4545 ,  A61P35/00 ,  C07D401/04 ,  A61K31/454 ,  C07D401/14 ,  C07D405/14 ,  C07D471/04 ,  C07D491/107 ,  C07D471/08 ,  A61K31/55 ,  A61K31/551 ,  C07D413/14 ,  A61K31/541 ,  A61K31/517 ,  A61K31/506 ,  A61K31/496 ,  A61K31/5377 ,  C07D409/14 ,  A61K31/4709 ,  A61K45/06

Abstract: The present disclosure relates to a compound of Formula (I) or a salt, a solvate, an isotopically enriched analog, a tautomer, a polymorph, a stereoisomer thereof, or a mixture of stereoisomers thereof, and their use for treating a tumor. The present disclosure also relates to a compound of Formula (I′) or a pharmaceutically acceptable salt, a solvate, an isotopically enriched analog, a tautomer, a polymorph, a stereoisomer thereof, or a mixture of stereoisomers thereof, and their use for treating a tumor.

公开(公告)号：US20220313829A1

公开(公告)日：2022-10-06

申请号：US17632612

申请日：2020-08-05

Applicant: SHANGHAITECH UNIVERSITY

Inventor： Xiaobao YANG ,  Biao JIANG ,  Xiaoling SONG ,  Ning SUN ,  Chaowei REN ,  Renhong SUN ,  Xiaojuan QU ,  Haixia LIU ,  Xing QIU

IPC: A61K47/55 ,  A61K47/54 ,  A61P35/00

Abstract: A bifunctional compound, or a pharmaceutically acceptable salt, an isomer, a prodrug, a polymorphic substance or a solvate thereof. The chemical structural formula of the bifunctional compound is represented as formula I, and the bifunctional compound can be used for preventing or treating cancers.